Generic drugmaker Zydus Cadila, the fifth largest pharmaceutical company in India, is set to invest about US$15.8 million in building an FDA-approved injectables-manufacturing plant. The news in August 2013 came just as Aurobindo Pharma announced plans to spin-off its injectables business to strengthen that side of its operations further.
Generics manufacturers increase investment in injectables
Home/Pharma News
|
Posted 30/08/2013
0
Post your comment

Zydus Cadila’s new manufacturing plant will be based in Vadodara, not far from its base in Ahmedabad. The company’s first focus will be on the US market, to be followed by Brazil and Europe. Aurobindo Pharma has plans to nearly quadruple sterile injectable capacity at a plant near Hyderabad.
The US market for injectables has been attracting widespread attention from the pharmaceutical industry. The number of drug shortages in the US has tripled in the last six years, and most have been the result of shortages in generic sterile injectables [1]. The injectable drug delivery market in the US has been predicted to grow to US$43.3 billion by 2017.
Medical technology company Becton Dickinson announced in March 2013 that FDA had approved the first drug in its line of pre-filled generic injectables (diphenhydramine hydrochloride, an antihistamine) [1]. The company has been investing heavily in its new manufacturing facility to produce these generic injectables.
All this comes in the wake of generics giant Mylan announcing in February 2013 that it had signed an agreement to acquire generic injectables maker Agila Specialties (Agila) from Strides Arcolab for US$1.6 billion [2]. According to IMS, the global generic injectables market is expected to grow at a compound annual growth rate of 13% from 2011–2017 driven by patent expiries.
References
1. GaBI Online - Generics and Biosimilars Initiative. New entrant to generic injectables market [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2013 Aug 30]. Available from: www.gabionline.net/Generics/News/New-entrant-to-generic-injectables-market
2. GaBI Online - Generics and Biosimilars Initiative. Mylan to acquire Strides Arcolab’s injectable generics business [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2013 Aug 30]. Available from: www.gabionline.net/Generics/News/Mylan-to-acquire-Strides-Arcolab-s-injectable-generics-business
Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.
Copyright – Unless otherwise stated all contents of this website are © 2013 Pro Pharma Communications International. All Rights Reserved.
Guidelines
FDA issues guidance on AI use in drug and biologicals regulatory decision making
ICH adopts Good Clinical Practice Guideline for clinical trials
Policies & Legislation
NPRA Malaysia trials new timelines for variation applications
Regulatory evolution and impact of simplified requirements for interchangeable biosimilars in the US
Most viewed articles
The best selling biotechnology drugs of 2008: the next biosimilars targets
Global biosimilars guideline development – EGA’s perspective
Related content
Bio-Thera partners with Tabuk in Saudi Arabia and SteinCares in LATAM
Klinge-Teva and MS Pharma agreements for Eylea and Stelara biosimilars in Europe and MENA
Biosimilars thrive as China’s biotech industry gains momentum
Greener Pharmaceuticals: WHO's call for innovative regulatory practices and eco-friendly innovations
Bio-Thera partners with Tabuk in Saudi Arabia and SteinCares in LATAM

Home/Pharma News Posted 18/02/2025
Klinge-Teva and MS Pharma agreements for Eylea and Stelara biosimilars in Europe and MENA

Home/Pharma News Posted 06/02/2025
Greener Pharmaceuticals: WHO's call for innovative regulatory practices and eco-friendly innovations

Home/Pharma News Posted 15/01/2025
The best selling biotechnology drugs of 2008: the next biosimilars targets

Post your comment